Drug Trial Radar · NCT06245291
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 1, 2024
Primary completion
Aug 1, 2024
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Arbutus Biopharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2a, open-label, multicenter study investigating the safety, tolerability, and antiviral activity of durvalumab administered at targeted times during a 48-week treatment period of imdusiran in virologically-suppressed CHB subjects
Conditions
- Hepatitis B, Chronic
Interventions
ImdusiranDrug
subcutaneous injection
DurvalumabDrug
intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of imdusiran and durvalumab in NA suppressed CHB subjectsTime frame: Up to 96 weeks
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
Infectious Diseases, AIDS and Clinical Immunology Research Center
Tbilisi, Georgia
LLC "Neolab"
Tbilisi, Georgia
Prince Of Wales Hospital - The Chinese University Of Hong Kong
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Punkt Zdrowia Hlebowicz Jakubowski Lekarze Spółka Partnerska
Gdansk, Poland
ID Clinic Arkadiusz Pisula
Mysłowice, Poland
Punkt Zdrowia Hlebowicz Jakubowski Lekarze Spółka Partnerska
Wroclaw, Poland
Arensia Exploratory Medicine Srl Romania in colaborare cu Institutul National de Boli Infectioase
Bucharest, Romania
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Chia-yi Christian Hospital
Chia-Yi City, Taiwan
Kaohsiung Medical University Chung-ho Memorial Hospital
Kaohsiung City, Taiwan
China Medical University Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
The Hiv Netherlands Australia Thailand Research Collaboration
Bangkok, Thailand
Srinagarind Hospital
Khon Kaen, Thailand
Naresuan University Hospital
Phitsanulok, Thailand
Imperial College Hospital
London, United Kingdom
Royal London Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.